Landos Biopharma (LABP) director Batycky returned to the company 3,600 Stock Option (right to buy)

Insider transactions reported

Alka Batycky (director at Landos Biopharma Inc., LABP) reported that they returned to the company 3,600 Stock Option (right to buy) on May 23, 2024.

Reporting person

Batycky Alka

Options and other derivatives

Holdings before and after

• Stock Option (right to buy): 3,600 to 0 direct

Footnotes from the filing

1. 1. Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ( Merger Agmt ), by and among the Issuer, AbbVie Inc. ( Guarantor ), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ( Parent ) and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ( Effective Time ), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes.

Transaction codes in this filing

Sale back to the company:

Code D marks a disposition back to the company under an exempt plan, as opposed to a sale in the market.

FAQ